Whether you are specifying your Bill of Materials for a new product or replacing an obsolete component, VEC-643 deserves your serious evaluation. Consult the official datasheet (revision 2.4 or later) for the most current information, and reach out to field application engineers for application-specific design reviews.
is an investigational Antibody-Drug Conjugate (ADC) designed for the targeted treatment of specific solid tumors. It combines a highly specific monoclonal antibody with a potent cytotoxic payload, linked via a stable chemical linker. The goal of VEC-643 is to deliver direct cell-killing agents to cancer cells while minimizing systemic toxicity. VEC-643